349 related articles for article (PubMed ID: 29482839)
1. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
Jareid M; Thalabard JC; Aarflot M; Bøvelstad HM; Lund E; Braaten T
Gynecol Oncol; 2018 Apr; 149(1):127-132. PubMed ID: 29482839
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
3. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
5. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
[TBL] [Abstract][Full Text] [Related]
6. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
8. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study.
Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Joensuu H; Pukkala E
Acta Oncol; 2016; 55(2):188-92. PubMed ID: 26243443
[TBL] [Abstract][Full Text] [Related]
9. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
[TBL] [Abstract][Full Text] [Related]
10. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.
Spotnitz ME; Natarajan K; Ryan PB; Westhoff CL
Obstet Gynecol; 2020 Feb; 135(2):319-327. PubMed ID: 31923062
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland.
Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
Obstet Gynecol; 2014 Aug; 124(2 Pt 1):292-299. PubMed ID: 25004338
[TBL] [Abstract][Full Text] [Related]
12. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
Wan YL; Holland C
Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
[TBL] [Abstract][Full Text] [Related]
14. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
[TBL] [Abstract][Full Text] [Related]
15. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the use of two new low-dose levonorgestrel-releasing intrauterine systems as contraceptives.
Bahamondes L; Bahamondes MV
Womens Health (Lond); 2012 May; 8(3):235-8. PubMed ID: 22554171
[TBL] [Abstract][Full Text] [Related]
19. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
20. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
